Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Duvelisib [1201438-56-3]
Katalog-Nummer T1988-100mg
Size : 100mg
Marke : TargetMol
Contact local distributor :
Telefonnummer : +1 850 650 7790
Duvelisib
Catalog No. T1988 CAS 1201438-56-3
Synonyms: INK1197, IPI-145
Duvelisib (INK1197) is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.
All products from TargetMol are for Research Use Only. Not for Human or Veterinary or Therapeutic Use.
Duvelisib, CAS 1201438-56-3
| Description | Duvelisib (INK1197) is an orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. |
| Targets&IC50 | PI3Kγ:243 pM(Ki), PI3Kβ:1564 pM(Ki), PI3Kδ:23 pM(Ki) |
| In vitro | In mice and rats treated with IPI-145 (10 mg/kg), the compound demonstrated favorable pharmacokinetics. In a rat CIA model, IPI-145 effectively prevented inflammation and preserved bone and cartilage integrity within the joints. |
| In vivo | IPI-145 exhibits potency in inhibiting the proliferation of various lymphocytes, including mouse B cells (EC50=0.5 nM), human B cells (EC50=0.5 nM), and human T cells (EC50=9.5 nM). |
| Synonyms | INK1197, IPI-145 |
| Molecular Weight | 416.86 |
| Formula | C22H17ClN6O |
| CAS No. | 1201438-56-3 |
Storage
Solubility Information
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 77 mg/mL (184.7 mM)
References and Literature
Citations
1. Xiong W, Jia L, Cai Y, et al.Evaluation of the anti-inflammatory effects of PI3Kδ/γ inhibitors for treating acute lung injury.Immunobiology.2023: 152753. 2. Sugawara T, Nevedomskaya E, Heller S, et al.Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.Molecular Oncology.2024